Advocacy at a Glance Lisa Ellington 5/13/22 Advocacy at a Glance Lisa Ellington 5/13/22 Commissioner Califf to Testify Before House Appropriations Committee; FDA Leaders Discussing FY 23 Budget Priorities; the House User Fee Bill Read More Advocacy at a Glance Lisa Ellington 5/6/22 Advocacy at a Glance Lisa Ellington 5/6/22 How FDA Is Funded; User Fee Reauthorization Legislation Released in the House; White House Conference on Hunger, Nutrition, and Health Announced for September Read More Analysis and Commentary Lisa Ellington 5/6/22 Analysis and Commentary Lisa Ellington 5/6/22 Alliance Members Encouraged to Submit Testimony to House Ag/FDA Subcommittee in Support of the Alliance’s FY 23 “Ask” Read More Analysis and Commentary Lisa Ellington 4/29/22 Analysis and Commentary Lisa Ellington 4/29/22 What Dr. Califf Said to the Senate; What CVM Director Dr. Solomon Said to the Alliance Read More Advocacy at a Glance Lisa Ellington 4/29/22 Advocacy at a Glance Lisa Ellington 4/29/22 Commissioner Califf Testifies in Senate; House/Senate Appropriations Leaders Have First Informal Chat About Total Spending for FY 23; Inspections, Budgeting, and the Pandemic Read More Analysis and Commentary STEVEN GROSSMAN 4/22/22 Analysis and Commentary STEVEN GROSSMAN 4/22/22 Q&A: the President’s Budget Request and our Hill visits to advocate for more FDA funding. Read More Advocacy at a Glance STEVEN GROSSMAN 4/22/22 Advocacy at a Glance STEVEN GROSSMAN 4/22/22 Alliance Concludes Second Round of Hill Visits to Request Increased FDA Funding; Tapes/transcripts for past/upcoming Alliance webinars Read More Analysis and Commentary STEVEN GROSSMAN 4/15/22 Analysis and Commentary STEVEN GROSSMAN 4/15/22 Summaries of the Alliance webinars with Associate Commissioner for Regulatory Affairs Judy McMeekin and with CFSAN Director Dr. Susan Mayne Read More Advocacy at a Glance STEVEN GROSSMAN 4/15/22 Advocacy at a Glance STEVEN GROSSMAN 4/15/22 More on President’s request for an FDA BA of $3.653 Billion Total; Volunteers Sought for Hill Meetings April 20/21 and beyond Read More Advocacy at a Glance STEVEN GROSSMAN 4/8/22 Advocacy at a Glance STEVEN GROSSMAN 4/8/22 Alliance Supports Administration Call for $336 Million Increase in FY 23; Encouraging Members of Congress to request increased FDA funding. Read More Analysis and Commentary STEVEN GROSSMAN 4/8/22 Analysis and Commentary STEVEN GROSSMAN 4/8/22 Summary of the Alliance webinar with CDER Director Dr. Patrizia Cavazzoni Read More Analysis and Commentary STEVEN GROSSMAN 4/1/22 Analysis and Commentary STEVEN GROSSMAN 4/1/22 Administration seeks FY23 FDA Increase of $336 Million; New Resources Support Broad Range of FDA Programs. Read More Advocacy at a Glance STEVEN GROSSMAN 4/1/22 Advocacy at a Glance STEVEN GROSSMAN 4/1/22 President’s FY 23 budget request FAQ’s Read More Analysis and Commentary STEVEN GROSSMAN 3/25/22 Analysis and Commentary STEVEN GROSSMAN 3/25/22 Forthcoming FY 23 President’s budget release and what to look for Part 2. Read More Advocacy at a Glance STEVEN GROSSMAN 3/25/22 Advocacy at a Glance STEVEN GROSSMAN 3/25/22 Encouraging Members of Congress to request increased FDA funding. Upcoming Alliance budget priorities webinar series with FDA leaders. Read More Analysis and Commentary STEVEN GROSSMAN 3/18/22 Analysis and Commentary STEVEN GROSSMAN 3/18/22 Forthcoming FY 23 President’s Budget Release and how to interpret the OMB “headline numbers” Part 1 Read More Advocacy at a Glance STEVEN GROSSMAN 3/18/22 Advocacy at a Glance STEVEN GROSSMAN 3/18/22 FY23 Appropriations: Ready, Set, Go. Part 2. Announcement of Alliance FY 23 Budget Priorities webinar series with FDA leaders. Read More Analysis and Commentary STEVEN GROSSMAN 3/11/22 Analysis and Commentary STEVEN GROSSMAN 3/11/22 Detail on the FDA’s FY 22 funding and implications for the FY 23 cycle. Read More Advocacy at a Glance STEVEN GROSSMAN 3/11/22 Advocacy at a Glance STEVEN GROSSMAN 3/11/22 FDA Receives $102 million increase in FY 22 Omnibus. Alliance campaign encourages Members of Congress to request increased FDA funding. Read More Advocacy at a Glance STEVEN GROSSMAN 3/4/22 Advocacy at a Glance STEVEN GROSSMAN 3/4/22 FY 22 Appropriations: completion nears; FY 23 Appropriations: Ready, Set, Go Part 1; Update on reconciliation. Read More Newer Posts Older Posts
Advocacy at a Glance Lisa Ellington 5/13/22 Advocacy at a Glance Lisa Ellington 5/13/22 Commissioner Califf to Testify Before House Appropriations Committee; FDA Leaders Discussing FY 23 Budget Priorities; the House User Fee Bill Read More
Advocacy at a Glance Lisa Ellington 5/6/22 Advocacy at a Glance Lisa Ellington 5/6/22 How FDA Is Funded; User Fee Reauthorization Legislation Released in the House; White House Conference on Hunger, Nutrition, and Health Announced for September Read More
Analysis and Commentary Lisa Ellington 5/6/22 Analysis and Commentary Lisa Ellington 5/6/22 Alliance Members Encouraged to Submit Testimony to House Ag/FDA Subcommittee in Support of the Alliance’s FY 23 “Ask” Read More
Analysis and Commentary Lisa Ellington 4/29/22 Analysis and Commentary Lisa Ellington 4/29/22 What Dr. Califf Said to the Senate; What CVM Director Dr. Solomon Said to the Alliance Read More
Advocacy at a Glance Lisa Ellington 4/29/22 Advocacy at a Glance Lisa Ellington 4/29/22 Commissioner Califf Testifies in Senate; House/Senate Appropriations Leaders Have First Informal Chat About Total Spending for FY 23; Inspections, Budgeting, and the Pandemic Read More
Analysis and Commentary STEVEN GROSSMAN 4/22/22 Analysis and Commentary STEVEN GROSSMAN 4/22/22 Q&A: the President’s Budget Request and our Hill visits to advocate for more FDA funding. Read More
Advocacy at a Glance STEVEN GROSSMAN 4/22/22 Advocacy at a Glance STEVEN GROSSMAN 4/22/22 Alliance Concludes Second Round of Hill Visits to Request Increased FDA Funding; Tapes/transcripts for past/upcoming Alliance webinars Read More
Analysis and Commentary STEVEN GROSSMAN 4/15/22 Analysis and Commentary STEVEN GROSSMAN 4/15/22 Summaries of the Alliance webinars with Associate Commissioner for Regulatory Affairs Judy McMeekin and with CFSAN Director Dr. Susan Mayne Read More
Advocacy at a Glance STEVEN GROSSMAN 4/15/22 Advocacy at a Glance STEVEN GROSSMAN 4/15/22 More on President’s request for an FDA BA of $3.653 Billion Total; Volunteers Sought for Hill Meetings April 20/21 and beyond Read More
Advocacy at a Glance STEVEN GROSSMAN 4/8/22 Advocacy at a Glance STEVEN GROSSMAN 4/8/22 Alliance Supports Administration Call for $336 Million Increase in FY 23; Encouraging Members of Congress to request increased FDA funding. Read More
Analysis and Commentary STEVEN GROSSMAN 4/8/22 Analysis and Commentary STEVEN GROSSMAN 4/8/22 Summary of the Alliance webinar with CDER Director Dr. Patrizia Cavazzoni Read More
Analysis and Commentary STEVEN GROSSMAN 4/1/22 Analysis and Commentary STEVEN GROSSMAN 4/1/22 Administration seeks FY23 FDA Increase of $336 Million; New Resources Support Broad Range of FDA Programs. Read More
Advocacy at a Glance STEVEN GROSSMAN 4/1/22 Advocacy at a Glance STEVEN GROSSMAN 4/1/22 President’s FY 23 budget request FAQ’s Read More
Analysis and Commentary STEVEN GROSSMAN 3/25/22 Analysis and Commentary STEVEN GROSSMAN 3/25/22 Forthcoming FY 23 President’s budget release and what to look for Part 2. Read More
Advocacy at a Glance STEVEN GROSSMAN 3/25/22 Advocacy at a Glance STEVEN GROSSMAN 3/25/22 Encouraging Members of Congress to request increased FDA funding. Upcoming Alliance budget priorities webinar series with FDA leaders. Read More
Analysis and Commentary STEVEN GROSSMAN 3/18/22 Analysis and Commentary STEVEN GROSSMAN 3/18/22 Forthcoming FY 23 President’s Budget Release and how to interpret the OMB “headline numbers” Part 1 Read More
Advocacy at a Glance STEVEN GROSSMAN 3/18/22 Advocacy at a Glance STEVEN GROSSMAN 3/18/22 FY23 Appropriations: Ready, Set, Go. Part 2. Announcement of Alliance FY 23 Budget Priorities webinar series with FDA leaders. Read More
Analysis and Commentary STEVEN GROSSMAN 3/11/22 Analysis and Commentary STEVEN GROSSMAN 3/11/22 Detail on the FDA’s FY 22 funding and implications for the FY 23 cycle. Read More
Advocacy at a Glance STEVEN GROSSMAN 3/11/22 Advocacy at a Glance STEVEN GROSSMAN 3/11/22 FDA Receives $102 million increase in FY 22 Omnibus. Alliance campaign encourages Members of Congress to request increased FDA funding. Read More
Advocacy at a Glance STEVEN GROSSMAN 3/4/22 Advocacy at a Glance STEVEN GROSSMAN 3/4/22 FY 22 Appropriations: completion nears; FY 23 Appropriations: Ready, Set, Go Part 1; Update on reconciliation. Read More
